Sartorius Stedim shares lose 2% but still show +26% over three months
The bioprocessing specialist declines within a CAC SBF 120 index that is heavily oriented downward. The drop comes a few days after a technical threshold was crossed, and the stock returns to its short-term moving average.
A pullback brings the stock back to its 20-day moving average (MM20) at €218.28
Shares of Sartorius Stedim Biotech fell 2.23% to €219.20, ranking 90th in a SBF 120 index that lost 1.64% during the session.
The decline erases part of the gains from last week: the stock had broken above its resistance at €228.40 on November 5 before retreating. It is now close to its 20-day moving average (MM20) (a gap of 0.42%), but remains above its 50-day moving average (MM50) at €208.33, 5.22% away.
The session took place in a Paris market weighed down by the fall on Wall Street, where the Nasdaq lost 5.52% on Thursday amid the correction in artificial intelligence. Over seven days, the loss reaches 4.03%, but the stock still gains 26.12% over three months.
Nine months 2026: higher free cash flow and confirmed targets
Investors have a recent fundamental reference point: the first nine months results, published on October 22, 2026, showed revenue growth of 4.3% and a free cash flow increase of 58.5%.
Among the drivers cited by the group during this publication, recurring activity linked to consumables remains the mainstay, and Asia-Pacific grew 10.6% at constant exchange rates.
Among the risks mentioned on the same date: sector volatility and the evolution of the geopolitical situation. According to the consensus of the analysts surveyed, the stock trades at 44 times earnings for the current fiscal year. The level to watch remains the support at €206.20, about 1% below the MM50.
